←Back to list

Ultima Genomics

Developer of genome-scale sequencing technology designed to offer analytical services to enterprises.
Developer of genome-scale sequencing technology designed to offer analytical services to enterprises.
Biotechnology 📍 Fremont, CA Founded 2016
Current Valuation
$3.6B
as of 2022-Q2
UNICORN

QL Price

$2.0B
-46% vs last round
QuantLogix's current estimate for Ultima Genomics, published 2026-09-27 — below the last disclosed round of $3.6B (2022-Q2).
Confidence
medium
Basis
secondary led
What backs this price
Last disclosed round $3.6B 2022-Q2 weight 0.05
Secondary market print $1.8B 2026-06-27 weight 0.58
How this price has held up
No round has priced for Ultima Genomics since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-27 and will be graded against the next priced round. See the full accuracy record →
How to actually get exposure to Ultima Genomics →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Ultima Genomics, 2026-09-27 (777badc6a7eccf91). The id pins this exact claim, so a citation stays checkable after the price moves. Model estimate for research — not a quote, target price, or investment advice.

IPO Outlookprivate

Is Ultima Genomics going public?
No. Ultima Genomics is private and has not filed to go public. There is no S-1 on file.
What is Ultima Genomics' valuation in 2026?
Ultima Genomics is valued at $3.6B as of 2022-Q2, set by its Series E ($229.25M, May 2022). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Ultima Genomics filed an S-1?
No public S-1 is on file for Ultima Genomics.
How much has Ultima Genomics raised?
Ultima Genomics has raised $600M in total, most recently a Series E of $229.25M in May 2022.
Is Ultima Genomics publicly traded — can you buy Ultima Genomics stock?
No. Ultima Genomics is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Ultima Genomics on its Pre-IPO Access Desk.
How to actually get exposure to Ultima Genomics →
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.

Company Profile

Founded
2016
HQ
Fremont, CA
Employees
304
Total Raised
$600M
Last Round
Series E — $229.25M (May 2022)
IPO Status
private

Fundraising Status

Series E · $229.25M · 4y 4mo ago
privateTotal raised $600M

Secondary Market

Implied price / share
$24.96
Last round price / share
$50.14
vs last round
-50.2%
Last round price vs secondary price
Last round vs current secondary price per share$50.14Last round$24.96Current
Secondary price return by period
Secondary market period returns3-month0.0%6-month+0.1%1-year-0.2%All-time-50.1%
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →

Latest Funding Round

RoundAmountDateLead InvestorPost-Money
Series E$229.25MMay 2022—$3.6B

Vertical Intelligence — Biotech / Gene Therapy

No name-verified sponsor record on ClinicalTrials.gov for Ultima Genomics — trials may run under a different legal entity, a partner sponsor, or not yet exist. Absence of a registry match is reported as-is, never guessed around.
Checked clinicaltrials.gov as of 2026-09-27. Re-checked weekly.

Talent Signal

Hiring trend
▶ Hiring steady
+7% vs 2026-08
Open roles
15
via greenhouse
Product-build share
47%
engineering, research, product, design
Trajectory
steady
product-led hiring — 47% of open roles build product; the rest are go-to-market and G&A.
Actively hiring with no tracked executive churn.
Open roles by month
Open roles by month14Aug '2615Sep '26
Open roles by function
Open roles by functionOther4Engineering3Research3Ops & People2Sales & GTM2Hardware1
■ product-building   ■ go-to-market / G&A
Field Service Engineer I, Development ProgramField Service Engineer II, ArizonaField Service Engineer II, UAESenior Field Application ScientistSenior Manufacturing EngineerSenior Scientist, Surface Chemistry
Counted from Ultima Genomics's live job board as of 2026-09-15; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
MedicalHealth CareBiotechnologyLife Science
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2022-Q2. Refreshed quarterly.